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The inhibitor of apoptosis proteins (IAPs) were 
initially identified as caspase inhibitors capable 
of blocking both extrinsic and intrinsic apop-
totic signals. Recent work has established di-
verse roles for the IAP family, in which they 
have been shown to regulate apoptosis through 
the  modulation  of  NF-B  signaling  down-
stream of several TNF family receptors and to 
play an essential role in the modulation of FAS-
induced cell death (Hu et al., 2006; Leulier et al., 
2006; Rigaud et al., 2006; Gaither et al., 2007; Lu 
et al., 2007; Petersen et al., 2007; Varfolomeev 
et al., 2007, 2008; Vince et al., 2007, 2008;   
Xu et al., 2007; Bertrand et al., 2008; Mahoney 
et al., 2008; Matsuzawa et al., 2008; Srinivasula 
and Ashwell, 2008; Wang et al., 2008; Csomos 
et al., 2009; Jost et al., 2009). All IAPs contain 
baculovirus inhibitory repeat domains that me-
diate  protein  binding,  and  several,  including 
cellular IAP-1 (cIAP-1) and cIAP-2, X-linked 
IAP (XIAP), and melanoma-IAP/Livin, contain 
RING  finger  E3  ubiquitin  ligase  domains, 
which can cause autoubiquitination as a means 
of  regulating  apoptosis  (Schile  et  al.,  2008; 
Srinivasula and Ashwell, 2008). IAPs are regu-
lated endogenously by second mitochondrial-
derived activator of caspases (SMAC), which 
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The inhibitor of apoptosis proteins (IAPs) have recently been shown to modulate nuclear 
factor B (NF-B) signaling downstream of tumor necrosis factor (TNF) family receptors, 
positioning them as essential survival factors in several cancer cell lines, as indicated by the 
cytotoxic activity of several novel small molecule IAP antagonists. In addition to roles in 
cancer, increasing evidence suggests that IAPs have an important function in immunity; 
however, the impact of IAP antagonists on antitumor immune responses is unknown. In this 
study, we examine the consequences of IAP antagonism on T cell function in vitro and in 
the context of a tumor vaccine in vivo. We find that IAP antagonists can augment human 
and mouse T cell responses to physiologically relevant stimuli. The activity of IAP antago-
nists depends on the activation of NF-B2 signaling, a mechanism paralleling that respon-
sible for the cytotoxic activity in cancer cells. We further show that IAP antagonists can 
augment both prophylactic and therapeutic antitumor vaccines in vivo. These findings 
indicate an important role for the IAPs in regulating T cell–dependent responses and sug-
gest that targeting IAPs using small molecule antagonists may be a strategy for developing 
novel immunomodulating therapies against cancer.
©  2010  Dougan  et  al.  This  article  is  distributed  under  the  terms  of  an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons.
org/licenses/by-nc-sa/3.0/).
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antitumor responses and responses to other forms of tumor 
immunotherapy may have implications for the use of these 
agents to treat cancer.
In this study, we examine the consequences of IAP an-
tagonism on T cell function both in vitro and in the context 
of a tumor vaccine in vivo. Unexpectedly, we find that IAPs 
function as negative co-stimulators during T cell stimulation 
and that small molecule IAP antagonists can augment both 
human and mouse T cell responses to physiologically relevant 
stimuli, including tumor antigens, without producing re-
sponses in unstimulated cells.
RESULTS
IAP antagonists have co-stimulatory activity  
in effector T cells
Effector T cells play a critical role in antitumor immunity. 
Consequently, the effect of IAP antagonism on T cell func-
tion could impact antitumor immune responses occurring in 
the context of IAP antagonist–mediated tumor cell death. To 
investigate how IAP antagonists may influence T cell func-
tion, we exposed CD4+ T cells isolated from mouse spleens 
to several IAP antagonists (M1/LBW-242, M2, and M3) or 
to a control compound of similar structure (C1/LCV-843; 
Gaither et al., 2007). We found no evidence of enhanced 
apoptosis in IAP antagonist–treated T cells regardless of whether 
the cells were left unstimulated or received a polyclonal- 
activating  signal  using  antibodies  directed  against  CD3   
and CD28 (Fig. 1 A and not depicted). Furthermore, in con-
trast to tumor cells that are sensitive to IAP antagonism, cas-
pase  3  cleavage  was  not  apparent  in  IAP  antagonist–treated   
T cells (Fig. 1 B).
Although apoptosis was not affected, IAP antagonists did 
have a significant effect on T cell function, leading to a sub-
stantial increase in T cell numbers after 72 h of culture (P < 
0.005 for 5 and 10 µg/ml; Fig. 1 C and Fig. S1). This effect 
was dependent on strong stimulation and was observed in 
both  anti-CD3–  and  anti-CD3/CD28–stimulated  cultures 
but not in cultures in which cells were left unstimulated or 
weakly  stimulated  (Fig.  1  C  and  Fig.  S1).  To  determine 
whether this increase in cell number resulted from an effect 
on proliferation, we stained CD4+ T cells with the dye CFSE 
and stimulated them in the presence of IAP antagonists. After 
3 d of stimulation, IAP antagonist–treated cultures showed 
substantially more CFSE dilution than controls, indicating 
increased proliferation (Fig. 1 D).
In addition to enhanced proliferation, T cells stimulated 
in the presence of IAP antagonists showed other signs of en-
hanced  activation.  IAP  antagonist  treatment  of  stimulated 
CD4+ T cells was associated with changes in surface marker 
expression  characteristic  of  enhanced  activation,  including 
more rapid increases in CD25 and decreases in CD62L and 
an overall increase in cell size (Fig. 1 E). After 1 d of culture, 
stimulated T cells treated with M1 reached a level of activa-
tion comparable with control cells after 3 d and, in combina-
tion with proliferation, produced overall increases in total 
activated T cells (P < 0.005 for days 1–3; Fig. 1 F).
interacts with IAP baculovirus inhibitory repeat domains via 
a tetrapeptide motif. Several pharmacologic SMAC mimetics 
have been developed that induce tumor death through bind-
ing to the RING domain containing IAPs and leading to 
ubiquitin-mediated destruction (Gaither et al., 2007; Petersen 
et al., 2007; Varfolomeev et al., 2007; Vince et al., 2007; 
Wang et al., 2008). These pharmacologic SMAC mimetics 
act as broad antagonists of the RING domain containing 
IAPs and are actively being investigated as a potential novel 
class of cancer chemotherapeutics.
In addition to roles in tumor biology, several studies sug-
gest important functions for the IAPs in immunoregulation. 
XIAP-deficient humans develop X-linked lymphoprolifera-
tive disease and were initially reported to lack NKT cells,   
although the specificity of this finding has recently been chal-
lenged (Rigaud et al., 2006; Marsh et al., 2009). XIAP-deficient 
mice have difficulty controlling Listeria monocytogenes infec-
tions and are more susceptible to infection with MHV-68 
(mouse herpes virus 68); however, the mechanism for this im-
munodeficiency is unknown and is not associated with de-
creased NKT cell function (Bauler et al., 2008; Rumble et al., 
2009). cIAP-2 is involved in a recurrent translocation in   
mucosal-associated lymphoid tissue lymphoma and has been re-
ported to function as an E3 ligase for BCL10 in lymphocytes, 
although the physiological importance of this activity is un-
known (Hu et al., 2006). More recently, the cIAPs were shown 
to be critical for c-Jun N-terminal kinase activation down-
stream of CD40 and to negatively regulate alternative NF-B 
activation by the BAFF (B cell activation factor of the TNF 
family) receptor (Matsuzawa et al., 2008; Vallabhapurapu et al., 
2008; Zarnegar et al., 2008). These findings position the cIAPs 
as potentially key regulators of B cell homeostasis, although 
how the cIAPs regulate B cell–dependent immune responses 
has, at present, been incompletely explored. In addition to 
roles in adaptive immunity, the cIAPs and XIAP have been 
shown to be required for NOD-1 and -2 (nucleotide biding 
and oligomerization domain 1 and 2) signaling and down-
stream cytokine production after exposure to muramyl di-
peptide (Bertrand et al., 2009; Krieg et al., 2009). Furthermore, 
cIAP-2–deficient mice show altered responses to lipopolysac-
charide that may indicate a role for cIAP-2 in inflammatory 
cytokine-induced apoptosis in macrophages (Conte et al., 
2006). Moreover, neuronal apoptosis inhibitor protein (NAIP), 
a member of both the NOD-like receptor and IAP families, 
is a component of the inflammasome and is required for con-
trol of Legionella pneumophila infections (Diez et al., 2003; 
Rigaud et al., 2006).
Although evidence now links the IAP family to regula-
tion of both tumor cell survival and immune function, the 
impact of IAP inhibitors on antitumor immune responses is 
unknown. In particular, the consequences of IAP antagonism 
in the key effector cells responsible for antitumor immunity 
such as CD4+ and CD8+ T cells, NKT cells, and NK cells has 
not been explored. Given the potential for IAP antagonists to 
simultaneously induce tumor cell death and modulate immu-
nity, understanding how IAP antagonism might alter nascent JEM VOL. 207, September 27, 2010 
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stimulation in the presence of IAP antagonists; however, after 
2 d in culture, the number of FOXP3-GFP–expressing cells 
remained essentially unchanged, demonstrating that IAP   
antagonism  does  not  selectively  expand  this  population   
(Fig. 1, G and H).
We next tested whether IAP antagonists could enhance 
cytokine production from stimulated CD4+ T cells in a man-
ner similar to their effect on other markers of T cell activa-
tion. Consistent with enhanced activation, isolated CD4+  
T  cells  treated  with  IAP  antagonists  and  stimulated  by   
To  exclude  the  possibility  that  increased  numbers  of 
CD4+CD25+ cells represented an increase in the T reg cell 
population, which has an overlapping surface phenotype with 
activated T cells (Fontenot et al., 2005), we stimulated CD4+ 
T cells isolated from mice expressing the transcription factor 
FOXP3 linked to GFP; FOXP3 is required for T reg cell de-
velopment and maintenance, and in these mice, all T reg cells 
are marked with GFP (Fontenot et al., 2005). As was ob-
served  in  wild-type  animals,  CD4+  T  cells  isolated  from 
FOXP3-GFP mice showed increased CD25 expression upon 
Figure 1.  IAP antagonists enhance mouse T cell proliferation and activation. (A–H) CD4+ T cells were positively selected from mouse spleens using 
magnetic beads and stimulated with 10 µg/ml plate-bound anti-CD3 (or as indicated) and 2 µg/ml anti-CD28 in the presence of IAP antagonist (M1) or 
control compound (C1) at 500 nM. (A) 5 × 105 CD4+ T cells were stimulated for 24 h. Annexin V and 7AAD staining were determined by flow cytometry. 
(B) Immunoblots for ZAP-70 and caspase 3 on total cell lysates from CD4+ T cells stimulated as indicated. (C and D) 105 CD4+ T cells were stimulated as 
indicated. (C) After 72 h, relative cell numbers were determined using CellTiter-Glo luminescent cell viability assay (Promega) and normalized to unstimu-
lated cultures treated with C1. (D) Cells were labeled with CFSE before stimulation, and fluorescence was measured after 72 h by flow cytometry. (E) 5 × 105 
CD4+ T cells were stimulated for the indicated periods of time, and CD25, CD62L, and forward scatter (FSC) were determined by flow cytometry.  
(F) Quantification of E using cell numbers determined by trypan blue exclusion. (G and H) 105 CD4+ T cells were isolated from the spleens of FOXP3-GFP 
knockin mice and stimulated for 72 h; CD25 and GFP were measured by flow cytometry. (H) Quantification of G using three replicates per group.  
(A–H) Error bars represent SEM. Results are representative of at least two independent experiments.2198 IAP inhibitors enhance co-stimulation | Dougan et al.
IFN- than cells treated with control compound (P = 0.007; 
Fig. 2 E). This effect was specific to stimulated cultures, as no 
cytokine was produced by cultures treated with IAP antago-
nists alone (Fig. 2 E). NK cell responses were also sensitive to 
IAP antagonism, as IAP antagonist–treated NK cells produced 
substantially more granulocyte-macrophage CSF (GM-CSF) 
after exposure to NKG2D ligand expressing YAC-1 cells, al-
though IAP antagonist treatment alone had no effect on GM-
CSF production (P < 0.0001; Fig. 2 F; Raulet et al., 2001).
Collectively, these findings indicate that IAP antagonists 
can augment lymphocyte co-stimulation. As is the case with 
co-stimulatory signals delivered through surface receptors 
(Greenwald et al., 2005), in the absence of antigen stimula-
tion, the IAP antagonists have no effect on any of the mea-
sured parameters of T cell activation, including proliferation, 
surface marker expression, and cytokine production; however, 
when T cells are given a strong activating signal, either with 
antibodies or peptide in the context of MHC, IAP antago-
nism leads to a significant enhancement in T cell function. 
Similar findings were observed with both NKT cells and NK 
cells, suggesting that IAP antagonists can broadly co-stimulate 
multiple cell types involved in antitumor responses and may 
be useful in augmenting antitumor immunity.
Human T cells are sensitive to IAP antagonists
We next decided to test whether our observations in mouse 
T cells could be generalized to human T cells. We first isolated 
human CD4+ T cells from the peripheral blood of healthy 
donors  and  stimulated  them  with  anti-CD3/anti-CD28   
in a manner analogous to our mouse T cell stimulations.   
Under these conditions, IAP antagonist treatment was associated 
with both dose-dependent enhancements in cytokine pro-
duction (P < 0.0001; Fig. 3, A and B) and changes in surface 
marker expression and cell size (Fig. 3 C) similar to those ob-
served with mouse cells. After 3 d of stimulation, activated 
CD25+CD62L T  cells  represented  nearly  29%  of  IAP   
increasing concentrations of anti-CD3 in the presence or ab-
sence of 2 µg/ml anti-CD28 produced substantially more IL-2 
than similarly cultured cells treated with control compound 
(P < 0.005 for 5 and 10 µg/ml; Fig. 2 A). The effect of IAP 
antagonism was dose dependent and was observed with three 
distinct compounds (P = 0.0002 for M1; Fig. 2 B and Fig. S2). 
In addition to effects on IL-2 production, levels of both IL-4 
and IFN- were increased in IAP antagonist–treated cultures 
(unpublished data). Isolated CD8+ T cells stimulated with anti-
CD3/CD28 also responded to IAP antagonist treatment with an 
increase in cytokine production, indicating a general activation-
enhancing effect of IAP antagonists on T cells (Fig. 2 C).
T cells are activated physiologically by the recognition of 
antigenic peptides bound to MHC on the surface of antigen-
presenting cells (Heemels and Ploegh, 1995). Consequently, 
we next sought to examine IAP antagonism in the context of 
peptide-restricted T cell activation. OTI CD8+ T cells, which 
recognize the OVA peptide SIINFEKL bound to MHC class I 
(Hogquist et al., 1994), were stimulated with peptide-loaded 
DCs in the presence of either the IAP antagonist M1 or con-
trol compound. As was observed in the context of activating 
antibodies, IAP antagonist treatment led to a dose-dependent 
enhancement in cytokine production with effects ranging 
from five- to sevenfold (P < 0.0001 for all M1 concentrations; 
Fig. 2 D); furthermore, IAP antagonists increased cytokine 
production at a range of peptide concentrations and when 
DCs were pulsed with whole OVA protein (Fig. S3; Hogquist 
et al., 1994).
In addition to peptide-reactive CD4+ and CD8+ T cells, 
both NKT cells and NK cells have been shown to play im-
portant roles in certain antitumor immune responses (Dougan 
and Dranoff, 2009). Consequently, we wondered how these 
cells types would respond to treatment with IAP antagonists. 
Consistent with the effect of IAP antagonists on peptide-specific 
responses, spleen cells stimulated with the NKT cell–specific 
agonist -galactosylceramide produced significantly more 
Figure 2.  IAP antagonists enhance the stimulation 
of multiple immune effectors. (A–C) CD4+ or CD8+  
T cells were isolated as in Fig. 1. (A) 105 CD4+ T cells were 
isolated and stimulated with anti-CD3 as indicated and  
2 µg/ml anti-CD28 for 72 h. M1 and C1 were used at  
500 nM. (B) 105 CD4+ T cells were isolated and stimulated 
with 10 µg/ml anti-CD3 and 2 µg/ml anti-CD28 for 48 h 
in the presence of M1 or control compound at the indi-
cated concentrations. (C) 105 CD8+ T cells were isolated 
and stimulated as in B for 48 h. M1 and C1 were used at 
500 nM. (D) 105 lymph node cells from RAG-deficient OTI 
transgenic mice were stimulated for 72 h by 0.5%  
formaldehyde-fixed bone marrow–derived DCs that had 
been pulsed with 10 µM/ml OVA peptide (SIINFEKL) 4 h 
before fixation. M1 or a control compound was added to the 
media at the indicated concentrations. (E) 5 × 105 spleen 
cells were stimulated with 100 ng/ml -galactosylce-
ramide (-galcer) or vehicle in the presence of M1 or control compound at 500 nM for 24 h. (F) 2 × 105 DX5+ NK cells were positively selected from 
mouse spleens using magnetic beads and stimulated for 48 h by co-culture with 4 × 104 YAC-1 cells in the presence of M1 or control compound at  
500 nM. (A–F) Cytokines were measured by ELISA. Error bars represent SEM. Results are representative of at least two independent experiments.JEM VOL. 207, September 27, 2010 
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was not altered by treatment with IAP antagonists, suggesting 
that the regulation of BCL10 abundance is not the principal 
mechanism of IAP antagonist activity in T cells (Fig. 4 B).
In tumor cells, IAP antagonist–mediated apoptosis de-
pends on the modulation of both alternative and classical   
NF-B signaling downstream of TNF family receptors. In these 
systems, the cIAPs constitutively down-regulate NF-B– 
inducing kinase (NIK), blocking alternative NF-B activa-
tion; however, the cIAPs are also indispensable in classical 
NF-B activation, promoting the association of receptor- 
interacting protein with TAK1 (transforming growth factor 
–activated  kinase  1)  through  receptor-interacting  protein 
ubiquitination (Gaither et al., 2007; Petersen et al., 2007;   
Varfolomeev  et  al.,  2007,  2008; Vince  et  al.,  2007,  2008;   
Mahoney et al., 2008; Wang et al., 2008). Regulation of   
TNF signaling by IAPs is conserved in Drosophila melanogaster, 
where DIAP2 (Drosophila IAP2) plays a critical role in the imd 
pathway, an immune response pathway orthologous to TNF 
signaling in mammals (Leulier et al., 2006).
Based on the evidence linking IAPs to NF-B modula-
tion, as well as the importance of NF-B in T cell biology, we 
examined classical and alternative NF-B signaling in T cells 
during IAP antagonist treatment (Karin and Lin, 2002). Stimu-
lated mouse CD4+ T cells treated with M1 showed enhanced 
p100 processing to p52, as well as enhanced p52 and RelB nu-
clear localization (Fig. 4, C and D); in addition, M1 had mod-
erate effects on IB- (inhibitor of NF-B ) levels (Fig. 4 C). 
Activation of alternative NF-B was also apparent in unstim-
ulated T cells exposed to IAP antagonists, demonstrating that, 
similar to their effects in tumor cells, IAP antagonists are suf-
ficient to activate alternative NF-B in T cells even in the ab-
sence of antigen signaling (Fig. 5 B and Fig. S4).
The observation of alternative NF-B signaling in IAP 
antagonist–treated T cells suggests a role for this pathway in 
IAP antagonist–mediated co-stimulation. To directly test   
the  importance  of  alternative  NF-B   
signaling  in  IAP  antagonist–treated   
T  cells,  we  evaluated  responses  to   
M1 in NIK-deficient alymphoplasia   
antagonist–treated cells compared with 18% of control cells; 
however,  in  contrast  to  mouse  cells,  the  total  fraction  of 
CD25+ T cells was only modestly increased (73.5 vs. 59.8%; 
Fig. 3 C). Also consistent with findings in the mouse, human 
cells were not activated by IAP antagonist treatment alone, 
further demonstrating a role for IAP antagonists in T cell co-
stimulation (Fig. 3 A).
We also assessed the ability to IAP antagonists to augment 
activation of T cells stimulated by the superantigen staphylo-
coccus  enterotoxin  B  (SEB),  in  addition  to  stimulation 
through activating antibodies. When human PBMCs were 
incubated with SEB, IAP antagonists enhanced cytokine pro-
duction by as much as fivefold (P < 0.0001 for M1 and M2; 
Fig. 3 D). Collectively, these results indicate that IAP antago-
nist treatment can co-stimulate T cell activation in both mice 
and humans.
Alternative NF-B signaling is required for IAP  
antagonist–induced T cell co-stimulation
The IAPs have been implicated in a wide range of signaling 
pathways that could modulate T cell activation (Srinivasula 
and Ashwell, 2008). Although caspases have a well-described 
role in T cell activation (Bidère et al., 2006) and several of the 
IAPs are known to regulate caspases, we found that relieving 
caspase inhibition does not appear to be the primary mecha-
nism underlying IAP antagonist activity in T cells. In addi-
tion to failing to activate caspase 3, IAP antagonists had an 
equivalent effect on T cell activation regardless of whether 
the cells were pretreated with the caspase inhibitor ZVAD-
fmk (Figs. 1 B and 4 A).
Because cIAP-2 has been reported to regulate NF-B   
activation through the ubiquitination and degradation of 
BCL10 (Hu et al., 2006), we also assessed the effects of the 
IAP antagonists on BCL10 abundance. Although a decrease 
in BCL10 was observed upon T cell stimulation, this change 
Figure 3.  Human T cells respond to IAP 
antagonists. (A–C) 105 human CD4+ T cells 
were isolated from the peripheral blood by 
positive selection using magnetic beads and 
stimulated with agonistic antibodies to 10 µg/ml 
anti-CD3 and 2 µg/ml anti-CD28 in the pres-
ence of M1 or a control compound at 500 nM 
(A and C) or as indicated (B). (A and B) IL-2 
was measured after 48 h in the culture super-
natant by ELISA. (C) Cells were stimulated for 
72 h, and CD25, CD62L, and forward scatter 
(FSC) were measured by flow cytometry.  
(D) 2 × 105 human PBMCs were incubated 
with SEB for 96 h in the presence of 500 nM M1 
or control compound. (A–D) Error bars represent 
SEM. Results are representative of at least 
three independent experiments.2200 IAP inhibitors enhance co-stimulation | Dougan et al.
through  the   
T cell recep-
tor  was  not 
required  for 
cIAP  reduc-
tion, as loss of the cIAPs occurred both in the presence and ab-
sence of stimulation (Fig. 5 A and Fig. S6). Consistent with our 
previous findings (Fig. 3 and Fig. 4, C–F) and other published 
work (Varfolomeev et al., 2007, 2008), degradation of the cIAPs 
in human T cells was associated with activation of alternative 
NF-B signaling (Fig. 5 B); as was observed with mouse T cells, 
alternative NF-B activation by IAP antagonists occurred in 
both stimulated and unstimulated cells (Fig. 5 B and Fig. S6).
To specifically address the role of the cIAPs in human   
T cells, we infected primary human CD4+ T cells with lenti-
viral constructs encoding short hairpin RNA directed against 
cIAP-1 and cIAP-2 (KD1–KD3; Moffat et al., 2006). Several 
of the evaluated constructs led to efficient knockdown of 
their targets in primary T cells (Fig. 5 C). In the mouse, loss of 
one cIAP leads to a compensatory increase in the other cIAP 
(Conze et al., 2005); however, transient knockdown of cIAP-1 
and cIAP-2 in human T cells led to only a minor compensa-
tory up-regulation of the other cIAP (Fig. 5 C). Efficient 
knockdown of either cIAP-1 or cIAP-2 in stimulated T cells 
was associated with increased IFN- production, suggesting a 
role of the cIAPs in negatively regulating activation (cIAP-1 
KD1, P = 0.001; cIAP-2 KD2, P = 0.009; cIAP-2 KD3, P < 
0.0001; Fig. 5 D).
cIAP-2 is regulated during T cell co-stimulation
These findings indicate a role for the cIAPs as regulators of 
T cell activation through their ability to negatively regu-
late alternative NF-B signaling. Given recent evidence 
that TNF family ligands can induce cIAP-1 degradation 
downstream of their receptors (Varfolomeev et al., 2008), 
we hypothesized that the cIAPs may be regulated as part of 
(aly/aly) mice (Miyawaki et al., 1994; Shinkura et al., 1999). 
Loss of NIK function prevents alternative NF-B signaling, 
which has been shown to induce a suppressive phenotype 
in mature but not naive CD4+ T cells (Ishimaru et al., 
2006); to avoid potentially confounding effects introduced 
by mixing naive and mature CD4+ T cells, we first isolated 
naive cells from aly/aly and aly/+ spleens using CD25 and 
CD44  expression  (Fig.  S5).  Stimulation  of  naive  aly/+ 
CD4+ T cells in the presence of IAP antagonists was asso-
ciated with a substantial increase in IL-2 secretion com-
pared  with  control  treatment.  In  contrast,  naive  aly/aly 
CD4+ T cells were resistant to IAP antagonist treatment 
(Fig. 4 E). As expected, p100 processing to p52 after IAP 
antagonist  treatment  was  also  blocked  in  aly/aly  CD4+  
T cells (Fig. 4 F).
These results demonstrate that IAP antagonists require 
NIK to augment T cell activation, likely acting through alter-
native NF-B signaling. Although this pathway is activated 
by IAP antagonists even in the absence of signaling through 
the  antigen  receptor,  our  results  indicate  that  alternative   
NF-B signaling alone cannot directly induce changes in T cell 
function. Signaling downstream of the antigen receptor likely 
activates  complementary  pathways  that  are  necessary  to   
enable IAP antagonists to effect a physiologically meaningful 
change in T cell function.
The cIAPs negatively regulate T cell activation
In principle, several IAPs could function as targets for IAP an-
tagonists in T cells. Both human and mouse T cells express 
cIAP-1, cIAP-2, and XIAP (Yang and Li, 2000). Consistent 
with findings in a range of different cell types exposed to struc-
turally diverse IAP antagonists (Gaither et al., 2007; Petersen   
et al., 2007; Varfolomeev et al., 2007; Vince et al., 2007; Wang   
et al., 2008), we observed decreases in cIAP-1 and cIAP-2 pro-
tein levels in human CD4+ T cells exposed to IAP antagonists, 
whereas XIAP levels remained constant (Fig. 5 A). Signaling 
Figure 4.  IAP antagonists enhance T cell  
activation through the induction of alternative 
NF-B signaling. (A–F) Mouse CD4+ T cells were 
isolated as in Fig. 1 or as indicated and stimulated 
with 10 µg/ml anti-CD3 and 2 µg/ml anti-CD28 in the 
presence of M1 or control compound at 500 nM.  
(A) CD4+ T cells were isolated and stimulated in the 
presence of the caspase inhibitor ZVAD-fmk or vehicle 
(DMSO). Data are presented as the ratio of IL-2 pro-
duction measured in culture supernatants from M1-
treated cells compared with control treatment.  
(B) Immunoblot for BCL10 in total cell lysates from 
stimulated CD4+ T cells. Lysates are identical to those 
depicted in Fig. 1 B. (C and D) Immunoblots using the 
indicated antibodies on total cell lysates (C) or puri-
fied nuclear lysates (D) from stimulated CD4+ T cells. 
(E) 105 naive T cells isolated from +/aly or aly/aly 
mouse spleens as depicted in Fig. S6 and stimulated 
in the presence of M1 or control compound. IL-2  
was measured by ELISA. (A and E) Error bars  
represent SEM. (F) Immunoblots using the indicated 
antibodies on cell lysates from total +/aly or aly/aly 
CD4+ T cells isolated using magnetic beads and im-
mediately lysed () or lysed after 24 h of stimulation 
(C1 and M1). (A–F) Results represent at least two 
independent experiments.JEM VOL. 207, September 27, 2010 
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CD4+ nor CD8+ T cell numbers were altered by 
M1 administration, nor were any clear effects ob-
served on NK cells or NK1.1+ T cells (Fig. 6,   
A and B). Although, as anticipated, broad T cell 
activation did not occur when mice were treated 
with M1, a small increase in the baseline number 
of CD69+ T cells was observed, possibly indicating 
a systemic increase in T cell activation (P = 0.03; Fig. 6 C). 
In contrast to the small increase in activation markers ob-
served in unstimulated cells, when CD4+ T cells were iso-
lated  from  M1-treated  mice  and  stimulated  ex  vivo  with 
anti-CD3/CD28 antibodies (in the absence of added inhibi-
tors), these cells showed a hyperresponsive phenotype, pro-
ducing substantially more IL-2 than cells isolated from control 
animals (P = 0.005; Fig. 6 D). These findings provide further 
evidence for a co-stimulatory effect of IAP antagonism and 
indicate that IAP antagonists may be able to augment im-
mune responses in vivo.
IAP antagonists can enhance the potency of tumor vaccines
Based on these findings, we hypothesized that IAP antagonists 
could function to augment tumor vaccine–induced responses. 
To evaluate IAP antagonist activity in vivo, we first used a 
suboptimal tumor cell vaccine in which irradiated B16 mouse 
melanoma cells are used to protect against live B16 challenge 
in syngeneic C57BL/6 mice. This approach has low intrinsic 
potency, but vaccine efficacy can be enhanced through a vari-
ety of immune manipulations, making it a useful system for 
studying  strategies  for  augmenting  antitumor  immunity 
(Dranoff et al., 1993; Jinushi et al., 2007). This system is further 
T cell co-stimulation. Activated T cells express several TNF 
family  co-stimulatory  receptors  that  activate  alternative 
NF-B; among these, glucocorticoid-induced TNF recep-
tor (GITR) is under active study in the context of tumor 
immunity, and thus we selected this molecule for more de-
tailed characterization (Watts, 2005). Activation of human 
T cells with anti-CD3/CD28 led to cIAP-2 up-regulation; 
however, additional co-stimulation using anti-GITR anti-
bodies was associated with a decrease in cIAP-2 concur-
rent with increased IFN- production and loss of p100 
(Fig. 5 E and not depicted). Levels of cIAP-1 were not 
clearly changed in anti-GITR–stimulated cells during the 
time points examined (unpublished data). These findings 
suggest  a  physiological  role  for  cIAP-2  downstream  of 
GITR co-stimulation.
In vivo exposure to IAP antagonists enhances  
T cell susceptibility to stimulation but does not lead  
to generalized T cell activation
We next sought to evaluate the consequences of systemic 
delivery of the IAP antagonist M1 on T cell and NK cell 
populations in the spleen. Consistent with our findings in 
cell culture, in the absence of additional signaling, neither 
Figure 5.  IAP antagonists target cIAP-1 and cIAP-2 in 
human T cells. (A and B) Immunoblots using the indicated 
antibodies on lysates from human CD4+ T cells isolated using 
magnetic beads. (A) Total lysates from CD4+ T cells were 
stimulated with 10 µg/ml anti-CD3 and 2 µg/ml anti-CD28 
and exposed to IAP antagonists (M1, M2, and M3), a control 
compound (C1), or vehicle () for 2 h. All compounds were 
used at 500 nM. (B) Total cell lysates or nuclear (nuc.) lysates 
from human CD4+ T cells. Cells were either stimulated as in A 
(top) or left unstimulated (bottom) for 24 h in the presence 
of vehicle, M1, or control compound, which were used at 
500 nM. (C and D) Human CD4+ T cells were isolated and 
stably transfected with lentiviral vectors encoding short 
hairpin RNAs against cIAP-1, cIAP-2, or nontargeting control 
(scramble [scr]). Three constructs (KD1–KD3) were used per 
gene. (C) Immunoblot using the indicated antibodies on ly-
sates from primary CD4+ T cells expressing the indicated 
short hairpin RNA constructs; quantification of knockdown 
is included below. (D) 2 × 104 cells were stimulated for 72 h. 
20 U/ml recombinant human IL-2 was added to all cultures. 
(E, left) Immunoblot using the indicated antibodies on total 
lysates from human CD4+ T cells stimulated with anti-CD3/
CD28; after 24 h, cells were exposed to 5 µg/ml anti-GITR 
antibodies as indicated. (right) IFN- production from GITR-
stimulated cells. (A–E) Cytokines were measured by ELISA. 
Error bars represent SEM. Results are representative of at 
least two independent experiments.2202 IAP inhibitors enhance co-stimulation | Dougan et al.
combined vaccine is mediated by an increase in T cell im-
munity (P = 0.003; Fig. 7 D; Jinushi et al., 2007). These 
findings establish as proof of principle that IAP antagonists 
can function as immunostimulants.
We next sought to assess the ability of IAP antagonists to 
augment immune responses in the context of a more effica-
cious tumor vaccine. Irradiated B16 vaccines comprised of 
cells engineered to secrete GM-CSF (GVAX) can provide 
potent  antitumor  immunity,  completely  protecting  mice 
from subsequent tumor challenge (Dranoff et al., 1993, Jinushi 
et al., 2007). However, when used on established tumors in 
a therapeutic setting, GVAX slows tumor growth but does 
not result in tumor eradication, making this an appropriate 
model to study IAP antagonists in the setting of a potent but 
incompletely effective vaccine (Jinushi et al., 2007).
We first examined B16 responses in mice vaccinated   
with either GVAX or GVAX in combination with M1.   
In combination-treated mice, IAP antagonist treatment was   
begun on day 1 and continued until day 6. On day 7, the lymph 
appropriate because we found that the IAP antagonists do not 
appear to have direct effects on B16 cells in culture. IAP an-
tagonist treatment does not alter B16 proliferation in vitro 
(Fig. 7 A); furthermore, IAP antagonists do not enhance apop-
tosis or caspase cleavage in B16 cells after irradiation (Fig. 7 B 
and Fig. S7).
Consistent with the effect of IAP antagonists in vitro and 
previous experiments studying B16 vaccines (Dranoff et al., 
1993), mice treated with either the IAP antagonist M1 or   
irradiated B16 melanoma cells alone showed no delay in   
tumor growth compared with controls after B16 challenge. 
However, combination treatment of mice with M1 and ir-
radiated B16 cells led to a 65% reduction in B16 growth   
after challenge (P = 0.02; Fig. 7 C). This reduction was   
associated with a significant increase in the frequency of 
CD8+ T cells specific for the B16 antigen TRP-2 (Jinushi   
et al., 2007) in the spleens of mice treated with the combi-
nation therapy compared with animals treated with irradi-
ated B16 alone, suggesting that, in part, the efficacy of the 
Figure 6.  Systemic delivery of IAP  
antagonists is well tolerated and leads to 
T cell hyperresponsiveness. (A–D) Mice were 
administered 750 µg M1 daily for 1 wk by 
gastric lavage. Spleen cells were harvested 
and analyzed by flow cytometry using the 
indicated markers. Six animals were used per 
group. (A) Comparison of total CD4+ and CD8+ 
T cells in mice treated with M1 or control (Ctl.) 
compound. (B) Quantification of NK1.1/CD3 
staining on spleen cells from M1-treated 
mice. (C, left) Flow cytometry plots showing 
CD69+CD3+ T cells in M1-treated and control 
animals. (right) Quantification of CD69/CD3 staining from the left panel. (D) 105 CD4+ T cells were isolated from mice treated with M1 and stimulated 
with anti-CD3/CD28 for 48 h. Labels refer to the treatment conditions of the mouse from which T cells were isolated for analysis; IL-2 was measured by 
ELISA. (A–D) Error bars represent SEM. Results are representative of two independent experiments.
Figure 7.  IAP antagonists augment a prophylactic  
antitumor vaccine. (A) 104 B16 cells were plated in the 
presence of IAP antagonists or control compound. Fold in-
crease was determined using CellTiter-Glo relative to time 0. 
(B) B16 cells were irradiated with 3.5 krad and cultured for 
24 h in the presence of IAP antagonists or control com-
pound. Apoptosis was assessed by flow cytometry using 
annexin V and 7AAD staining. Results are representative of 
at least two independent experiments. (C) Tumor growth 
curves for C57BL/6 mice injected with 5 × 105 B16 mela-
noma cells on day 0. Mice either did not receive a vaccine or 
received vaccines comprising 150 mg/kg M1, 5 × 105 irradi-
ated B16 cells, or 150 mg/kg M1 and irradiated B16 cells 
before tumor challenge. Eight mice were used per group. 
Data are consistent with two independent experiments using 
several distinct schedules and doses. (A–C) Error bars repre-
sent SEM. (D) On day 14, 2.5 × 105 CD8+ T cells were isolated 
from the spleens of mice vaccinated as indicated and stimu-
lated by irradiated spleen cells pulsed with TRP-2 peptide or 
vehicle. IFN-–reactive cells were determined by the  
enzyme-linked immunosorbent spot.JEM VOL. 207, September 27, 2010 
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node cultures from combination-treated mice even when the 
differences in cell number were taken into account (unpub-
lished data).
We  next  examined  whether  IAP  antagonist  treatment 
could augment the effect of GVAX on tumor growth. Mice 
were vaccinated 1 d after B16 challenge with either GVAX 
alone or GVAX followed by daily treatmrnt with M1 for   
1 wk. Combination-treated mice showed significantly de-
creased tumor growth rates compared with animals treated 
with GVAX or M1 alone (P < 0.05 from day 10–25), al-
though median survival was not prolonged (Fig. 8, D and E). 
Although additional studies to identify optimal dosing regi-
mens are required, these results confirm the immunomod-
ulatory activity of the IAP antagonists and establish the ability 
of these drugs to improve responses to tumor vaccines in 
both prophylactic and therapeutic settings.
DISCUSSION
Collectively,  our  findings  establish  the  IAPs  as  important 
regulators of T cell activation and define IAP antagonists as a 
novel  class  of  immunomodulating  agent.  Unlike  conven-
tional adjuvants, IAP antagonists act in a co-stimulatory ca-
pacity, enhancing immune responses to physiological immune 
signals in both mice and humans, while lacking intrinsic stim-
ulatory capacity. The co-stimulatory effect is striking in   
T cells where IAP antagonism in the context of stimulation 
leads to enhanced cytokine secretion, as well as increased 
proliferation and expression of activation markers.
IAP antagonism appears to co-stimulate T cells by block-
ing the ability of the cIAPs to inhibit alternative NF-B sig-
naling, likely through their ability to regulate NIK, as has 
been shown in a variety of other cell types (Gaither et al., 
2007; Lu et al., 2007; Petersen et al., 2007; Varfolomeev et al., 
2007, 2008; Vince et al., 2007, 2008; Bertrand et al., 2008; 
Mahoney et al., 2008; Vallabhapurapu et al., 2008; Zarnegar 
et al., 2008). T cells from mice harboring spontaneous muta-
tions in NIK are resistant to IAP antagonism, and decreases in 
cIAP-1 and cIAP-2 after antagonist treatment are associated 
with rapid activation of alternative NF-B. Similarly, knock-
down of cIAP-1 and cIAP-2 enhances cytokine production 
from stimulated T cells.
In  human  T  cells,  cIAP-2  is  regulated  after  signaling 
downstream of GITR. This finding indicates a potential 
physiological role for the IAPs in the regulation of GITR co-
stimulation, which is known to depend in part on alternative 
NF-B (Watts, 2005). Given the range of TNF family recep-
tors now known to signal through the IAPs, this finding   
further suggests that in T cells, the IAPs may play a role 
downstream of TNF receptor co-stimulation more broadly. 
If this hypothesis is born out, then IAP antagonists could 
function as activators of multiple co-stimulatory receptors   
simultaneously, while bypassing any requirement for co- 
stimulatory receptor ligation. Such co-stimulatory activity by 
a small molecule may be useful in a wide variety of immuno-
therapies, including vaccine development and the treatment 
of immunodeficiencies. Indeed, several different agonistic 
nodes that drain the vaccine site were harvested and cultured 
with irradiated B16 cells. Lymph node cell cultures from mice 
treated with combination therapy produced substantially 
more IFN- in response to B16 cells than did cells taken 
from mice treated with either M1 or GVAX alone (P = 0.03; 
Fig. 8 A). Furthermore, significantly fewer B16 cells remained 
in the lymph node cultures derived from combination- 
treated  mice  compared  with  cultures  from  GVAX-  or   
M1-treated animals (P = 0.03; Fig. 8 B). This loss of B16 cells 
was  likely  caused  by  enhanced  cytotoxicity  by  cells  from 
combination-treated animals because these cultures showed 
enhanced B16 cell killing in chromium release assays (unpub-
lished data). In addition to lymph node responses, IFN- 
production from NK cells harvested from the spleens of vac-
cinated mice and co-cultured with YAC-1 cells was also en-
hanced in combination-treated animals compared with mice 
treated with GVAX alone (P < 0.0001; Fig. 8 C). Lymph 
nodes harvested from combination-treated animals were only 
marginally  larger  than  lymph  nodes  from  GVAX-treated 
mice, though, and contained similar numbers of B cells,   
T cells, and DCs, as well as activated and regulatory T cell 
subsets (Fig. S8). IFN- production was higher in lymph 
Figure 8.  IAP antagonists enhance immune responses to a thera-
peutic antitumor vaccine. (A–C) On day 0, mice were vaccinated with 
irradiated B16 cells engineered to secrete GM-CSF (GVAX) and were either 
left untreated or were given a 6-d course of 1,000 µg/day M1 by gastric 
lavage (GVAX M1). Untreated mice () and mice given M1 in the absence 
of GVAX (M1) were used as controls. (A and B) Vaccination site draining 
lymph nodes were harvested on day 7 and resuspended in 500 µl RPMI 
containing 10 U/ml recombinant human IL-2. Lymph node cells were in-
cubated with 2 × 105 irradiated B16 cells for 4 d. (A) IFN- was measured 
in the culture supernatants by ELISA. (B) Total viable B16 cells were quan-
tified by trypan blue exclusion. (C) 2 wk after vaccination, NK cells were 
isolated, activated, and analyzed as in Fig. 2 F. (A–C) Results are represen-
tative of at least two independent experiments with three to four mice 
per group. (D and E) On day 0, mice were challenged with 2 × 105 B16 
cells. Mice were vaccinated as in A–C starting on day 1. Tumor growth (D) 
and survival (E) for mice after challenge are shown. Results represent the 
combination of three similarly designed, independent experiments with 
similar results for a total of 12–18 mice per group. (A–E) Error bars repre-
sent SEM.2204 IAP inhibitors enhance co-stimulation | Dougan et al.
(mouse mAb DT5D3; Miltenyi Biotec), IB- (mouse mAb clone 112B2; 
Cell Signaling Technology), p100/p52 (rabbit pAb; Cell Signaling Technol-
ogy), RelB (rabbit pAb; Cell Signaling Technology), USF-2 (rabbit pAb; 
Santa Cruz Biotechnology, Inc.), XIAP (clone 28; BD), and ZAP-70 (rabbit 
mAb clone D1C10E; Cell Signaling Technology) were also used.
Flow cytometry and immunoblotting. Single cell suspensions were made 
from resected spleens or lymph nodes by mechanical disruption; red blood 
cells were removed by hypotonic lysis. CD4, CD8, or DX5+ cells were puri-
fied either from organ suspensions (mouse) or peripheral blood (human) using 
magnetic beads conjugated to the indicated antibodies (Miltenyi Biotec);   
purifications were performed according to manufacturer’s instructions. Cells 
were then washed and stained for 30 min on ice with the indicated antibodies 
in PBS with 1% inactivated fetal calf serum; for most experiments, Fc recep-
tors were blocked using an unconjugated Fc-blocking antibody (BD) 15 min 
before staining. For Western blot analysis, cells were lysed in 1% NP-40 or 
using a cytoplasmic/nuclear fractionation kit (Thermo Fisher Scientific). Pro-
tein concentration was quantified by bicinchoninic acid assay (Thermo Fisher 
Scientific), and 30 µg of protein was loaded per lane onto 12% acrylamide 
gels. SDS-PAGE was followed by transfer to nitrocellulose and immunoblot-
ting using the indicated primary antibodies. Secondary antibodies conjugated 
to alkaline phosphatase were purchased from Jackson ImmunoResearch Lab-
oratories, Inc. and used at 1:5,000 dilution.
ELISA. All ELISA kits were purchased from BD and used according to the 
manufacturer’s instructions.
Lentiviral knockdown. 2 × 104 CD4+ T cells isolated by positive selection 
from human peripheral blood were infected by spin transduction with highly 
concentrated lentiviral particles (Broad Institute and Sigma-Aldrich) using a 
multiplicity of infection of 3. 2 µg/ml puromycin was added 48 h after infec-
tion. Cells were analyzed 4–6 d later. Infections and subsequent cultures 
were performed in the presence of 2 µg/ml plate-bound anti-CD3, 2 µg/ml 
anti-CD28, and 20 U/ml recombinant human IL-2 in 100 µl RPMI. cIAP-1 
KD1, 5-GCCGAATTGTCTTTGGTGCTTCTCGAGAAGCACCAAAG-
ACAATTCGGC-3; cIAP-1 KD2, 5-GCTGCGGCCAACATCTTCAAA-
CTCGAGTTTGAAGATGTTGGCCGCAGC-3; cIAP-1 KD3, 5-TGGT-
TAAATCTGCCTTGGAAACTCGAGTTTCCAAGGCAGATTTA-
ACCA-3;  cIAP-2  KD1,  5-CAGTTCGTACATTTCTTTCATCTC-
GAGATGAAAGAAATGTACGAACTG-3; cIAP-2 KD2, 5-GCAGAGT-
CATCAATTATCCATCTCGAGATGGATAATTGATGACTCTGC-3; 
and  cIAP-2  KD3,  5-GCACTACAAACACAATATTCACTCGAGT-
GAATATTGTGTTTGTAGTGC-3 were used.
Anti-GITR co-stimulation. 3 × 106 CD4+ human T cells isolated from the 
peripheral blood by positive selection were incubated with either 2 or 10 µg/ml 
of plate-bound anti-CD3 and 2 µg/ml anti-CD28 for 24 h in 500 µl RPMI. 
After 24 h, T cells were either continued on anti-CD3/CD28 stimulation for 
an additional 14–24 h or stimulated with plate-bound anti-CD3/CD28 and   
5 µg/ml anti-GITR for the same period of time. Co-stimulation was verified 
by measuring cytokine production in the culture supernatants by ELISA.
Ex vivo stimulation. Mice were treated daily with M1 by gastric lavage at 
a dose of 750 µg per day. After 1 wk, mice were euthanized, and CD4+  
T cells were isolated by positive selection using magnetic beads. 106 CD4+  
T cells were incubated with 5 µg/ml of plate-bound anti-CD3 and 2 µg/ml 
anti-CD28 for 48 h in 500 µl RPMI.
Prophylactic B16 vaccine. On days 0 and 7, mice were given a subcuta-
neous injection containing 5 × 105 irradiated (3.5 krad) B16 cells in con-
junction with oral administration of M1 or control compound at either 150 
or 30 mg/kg. On day 14, mice were challenged with a subcutaneous injec-
tion containing 5 × 105 live B16 cells.
B16 GVAX. On day 0, mice were challenged with a subcutaneous injec-
tion containing 2 × 105 live B16 cells. On day 1, mice received a subcutaneous 
mAbs against TNF family receptors are currently under in-
vestigation as targets for immunotherapy for cancer; these   
include antibodies to GITR, CD134 (OX40), and CD137 
(4-1BB), with anti-CD137 antibodies now in phase I/II testing 
(Dougan and Dranoff, 2009).
In mice, we have shown that in vivo administration of 
IAP antagonists can augment the efficacy of both prophylac-
tic and therapeutic tumor vaccines. IAP antagonist treatment 
is associated with systemic hyperresponsive T cells in the ab-
sence of overt autoimmunity or expansion of the T cell com-
partment. After vaccination, IAP antagonist treatment leads 
to augmented antitumor responses that are associated with 
delayed tumor growth and prolonged survival. These find-
ings demonstrate that the effects of IAP antagonism observed 
in culture can, at least in part, be harnessed in vivo to modu-
late immune responses. Future work will be necessary to fully 
optimize this approach, in particular focusing on alternative 
conditions for IAP antagonist delivery and the introduction 
of optimal antigenic signals. Our results in cell culture suggest 
that certain threshold levels of stimulation substantially in-
crease the efficacy of IAP antagonists, as indicated by the 
change in the magnitude of the IAP antagonist effect during 
anti-CD3 dose titration (Figs. 1 C and 2 A). Moreover,   
although we have not found evidence for apoptosis regula-
tion by the IAPs in cell types examined in these experiments, 
further investigations may well reveal circumstances under 
which the antiapoptotic activity of the IAPs is indispensable 
for T cell survival or function.
The unanticipated activity of the IAP antagonists in   
T cells and other effectors of antitumor immunity also en-
ables a novel approach to chemotherapy for cancer. IAP an-
tagonists could have a synergistic effect on tumors. Through 
direct cytotoxicity, IAP antagonists could increase tumor cell 
death, leading to increased presentation of tumor antigens to 
the immune system. At the same time, we have now demon-
strated that inhibiting IAPs removes a physiological signaling 
brake, allowing for enhanced responses from both CD4+ and 
CD8+ T cells as well as other key antitumor effector cells, in-
cluding NKT cells and NK cells.
MATERIALS AND METHODS
Animals. C57BL/6 and BALB/c wild-type mice were purchased from Ta-
conic or The Jackson Laboratory or bred in house. Aly/aly mice were obtained 
from G. Benichou (Massachusetts General Hospital, Boston, MA; Miyawaki   
et al., 1994). FOXP3-GFP knockin mice were obtained from A. Rudensky 
(Memorial Sloan-Kettering Cancer Center, New York, NY; Fontenot et al., 
2005). All animal experimentation was performed in accordance with institu-
tional guidelines and the review board of Harvard Medical School, which 
granted permission for this study, and was approved by the Association for   
Assessment and Accreditation of Laboratory Animal Care–accredited Dana- 
Farber Cancer Institute Institutional Animal Care and Use Committee.
Antibodies. All antibodies used for flow cytometry were obtained from 
BD. BCL10 (rabbit pAb; Cell Signaling Technology), caspase 3 (rabbit pAb; 
Cell Signaling Technology), human CD3 (mouse mAb clone HIT3a; BD), 
mouse CD3 (hamster mAb clone 145-2C11; BD), human CD28 (mouse 
mAb clone CD28.2; BD), mouse CD28 (hamster mAb clone 37.15; BD), 
cIAP-1 (goat pAb; R&D Systems), cIAP-2 (mouse mAb clone 315304; 
R&D Systems), GAPDH (mouse mAb clone MAB374; Millipore), GITR JEM VOL. 207, September 27, 2010 
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